How to Get Farxiga (Dapagliflozin) in Utah

Why Dapagliflozin Access Matters in Utah

Dapagliflozin is an SGLT2 inhibitor with three distinct FDA approvals: type 2 diabetes, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD). The DAPA-HF trial (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) [1]. That benefit applied regardless of diabetes status.

A Growing Patient Population

Utah has one of the fastest-growing adult populations in the U.S., and age-adjusted rates of type 2 diabetes continue to climb. According to the CDC's National Diabetes Statistics Report, roughly 8.7% of Utah adults had diagnosed diabetes in recent surveillance years [2]. Heart failure and CKD prevalence track upward with diabetes duration, making access to SGLT2 inhibitors a practical concern for thousands of Utahns.

Clinical Guideline Support

The 2022 ADA Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD [3]. The ACC/AHA heart failure guidelines list dapagliflozin as a Class I recommendation for HFrEF [4]. These guideline positions mean most insurers have a clinical framework for covering the drug, even when prior authorization is required.

Step-by-Step: Getting a Farxiga Prescription in Utah

The path from evaluation to a filled prescription involves a clinical visit, baseline labs, a prescription, possible prior authorization, and pharmacy dispensing. Each step has Utah-specific considerations.

Step 1: Clinical Evaluation

Any Utah-licensed MD, DO, NP, or PA can prescribe dapagliflozin. Utah's Nurse Practice Act grants full practice authority to APRNs after 2,000 hours of supervised practice, so many NPs in endocrinology, cardiology, and primary care clinics prescribe SGLT2 inhibitors without physician co-signature. Schedule a visit with a provider who manages your underlying condition (diabetes, heart failure, or CKD).

Step 2: Baseline Labs

Before starting Farxiga, expect your provider to order at a minimum:

• Estimated GFR (eGFR): Farxiga's FDA label advises checking kidney function before initiation. The diabetes indication recommends against starting if eGFR is <25 mL/min/1.73 m² [5].
• Basic metabolic panel (BMP): Screens for baseline electrolytes, bicarbonate, and creatinine.
• Hemoglobin A1c: Establishes glycemic baseline for diabetes patients.
• Urinalysis: Rules out active urinary tract infection, which can worsen on SGLT2 therapy.

Labs are available at any Quest, LabCorp, ARUP (headquartered in Salt Lake City), or hospital-affiliated draw site across Utah.

Step 3: Prescription and Prior Authorization

Once labs clear, your provider writes a prescription for dapagliflozin 5 mg or 10 mg once daily. Most commercial insurers in Utah (SelectHealth, Regence BlueCross BlueShield, PEHP, Molina) require prior authorization for brand Farxiga. The typical PA packet includes:

• Documented diagnosis (ICD-10 code)
• Recent A1c or BNP/NT-proBNP and eGFR
• Trial or contraindication to metformin (for diabetes indication)
• Clinical notes supporting medical necessity

PA turnaround time is usually 48 to 72 hours for commercial plans.

Step 4: Pharmacy Fill

After PA approval, any retail or specialty pharmacy in Utah can fill the prescription. Major chains (Walgreens, CVS, Smith's, Harmons) stock brand Farxiga. Patients in rural areas (e.g., southern Utah, Uintah Basin) can use mail-order pharmacy services for direct-to-door delivery.

Telehealth Options for Farxiga in Utah

Utah law allows licensed telehealth providers to prescribe dapagliflozin after an appropriate clinical encounter. This is a real option for patients who live far from specialty clinics.

How Utah Telehealth Prescribing Works

Under Utah Code §26-60 (Telehealth Act), providers can establish a patient-provider relationship via real-time audio-video consultation. No in-person visit is required before prescribing a non-controlled medication like dapagliflozin. The provider must hold an active Utah license or practice under an interstate compact (Utah participates in the Interstate Medical Licensure Compact).

What to Expect from a Telehealth Visit

A typical telehealth appointment for Farxiga takes 15 to 25 minutes. The provider reviews your medical history, current medications, recent labs, and indication for dapagliflozin. If you do not have recent labs, the provider will order them at a local draw site and write the prescription once results are reviewed. Some telehealth platforms send the prescription directly to your preferred Utah pharmacy; others use their own affiliated mail-order pharmacy.

Choosing a Telehealth Platform

Look for platforms that meet these criteria: prescribers licensed in Utah, ability to submit prior authorization on your behalf, and transparent pricing for the visit itself. HealthRX connects Utah patients with board-certified providers experienced in SGLT2 inhibitor prescribing, and our clinical team handles PA paperwork as part of the consultation.

Utah Medicaid and Farxiga: What You Need to Know

Utah Medicaid does not currently cover Farxiga. This is a meaningful barrier for the roughly 390,000 Utahns enrolled in Medicaid or the state's expansion population.

Why Coverage Is Absent

State Medicaid preferred drug lists (PDLs) prioritize lower-cost alternatives. For type 2 diabetes, Utah Medicaid covers metformin, sulfonylureas, and certain DPP-4 inhibitors as first-line options. SGLT2 inhibitors and GLP-1 receptor agonists sit behind step-therapy walls, and Farxiga specifically is listed as non-preferred or not covered on the current PDL.

Workarounds for Medicaid Patients

Medicaid patients with heart failure or CKD may qualify for exception requests when the prescriber documents that dapagliflozin is medically necessary and no covered alternative addresses the same indication. The DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001), a result that applies to CKD patients with or without diabetes [6]. Citing this evidence in an exception request strengthens the case.

Other cost pathways include AstraZeneca's patient assistance program for qualifying low-income patients and 503A compounded dapagliflozin (discussed below).

Commercial Insurance and Cost Strategies

Most commercially insured Utah patients can access Farxiga after prior authorization. The out-of-pocket cost varies widely based on plan design.

Copay Cards and Manufacturer Support

AstraZeneca offers a Farxiga Savings Card that reduces the copay to as low as $0 per month for eligible commercially insured patients. The card covers up to a specified annual maximum. It does not apply to government insurance (Medicare, Medicaid, Tricare).

503A Compounding in Utah

Utah licenses 503A compounding pharmacies under the Utah Pharmacy Practice Act. These pharmacies can compound dapagliflozin into oral capsules or other formulations when a patient has a valid prescription and a documented clinical need (such as allergy to an inactive ingredient in the brand product or a need for a non-standard dose). Compounded dapagliflozin may cost less than brand Farxiga, especially for patients without insurance coverage. Not every 503A pharmacy stocks dapagliflozin, so call ahead.

Price Comparison Table

| Source | Approximate 30-Day Cost (10 mg) | |---|---| | Brand Farxiga, no insurance | $550, $620 | | Brand Farxiga, with copay card | $0, $30 | | Brand Farxiga, after commercial PA | Plan copay (typically $30, $75 tier 3) | | 503A compounded dapagliflozin | $80, $200 (varies by pharmacy) |

Prices reflect typical 2025 to 2026 ranges and fluctuate by pharmacy and plan.

Prior Authorization: What Utah Providers Must Submit

Prior authorization is the single most common delay in starting Farxiga. Understanding what insurers need helps patients and providers move faster.

Required Documentation

Utah's largest commercial plans (SelectHealth, Regence, PEHP) share a similar PA template:

1. Diagnosis and ICD-10 code: E11.x (type 2 diabetes), I50.x (heart failure), or N18.x (CKD).
2. Lab results: A1c within 90 days (diabetes), NT-proBNP or echocardiogram (heart failure), eGFR and urine albumin-to-creatinine ratio (CKD).
3. Step therapy documentation: Evidence that the patient tried metformin for at least 90 days (diabetes indication) or that metformin is contraindicated.
4. Clinical rationale: A brief note explaining why dapagliflozin is the appropriate SGLT2 inhibitor over alternatives.

Timeline and Appeals

Initial PA decisions arrive within 48 to 72 hours for standard requests. Urgent requests (patient currently hospitalized, transitioning from inpatient to outpatient) are processed within 24 hours. If denied, the provider can file a peer-to-peer review or formal appeal. The ADA's 2024 position statement on prior authorization calls PA requirements for SGLT2 inhibitors "a barrier to evidence-based care" and recommends streamlining access for guideline-concordant prescribing [7].

Monitoring After You Start Dapagliflozin

Getting the prescription filled is only the first milestone. Ongoing monitoring keeps therapy safe.

First 1 to 3 Months

Providers typically recheck eGFR and a basic metabolic panel within 1 to 3 months of initiation. A small, expected dip in eGFR (up to 10 to 15%) can occur in the first weeks. This hemodynamic effect stabilizes and does not indicate kidney damage. The CREDENCE trial confirmed that this initial eGFR dip with SGLT2 inhibitors was followed by long-term preservation of kidney function [8].

Ongoing Monitoring

After the initial period, most providers recheck labs every 3 to 6 months. Watch for symptoms of:

• Genital mycotic infections: The most common side effect, occurring in roughly 6 to 8% of women and 3 to 4% of men on SGLT2 inhibitors [5].
• Volume depletion: Especially relevant in Utah's dry climate and at higher altitudes, where insensible water losses are greater.
• Euglycemic diabetic ketoacidosis (DKA): Rare (incidence <0.1%) but serious. Patients should know to seek emergency care if they develop nausea, vomiting, and abdominal pain, even with normal blood glucose readings.

Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine and a DAPA-HF investigator, has noted: "SGLT2 inhibitors have fundamentally changed how we treat heart failure, but clinicians must remain vigilant about volume status and ketoacidosis risk, particularly in patients who are fasting or acutely ill" [1].

Transferring a Farxiga Prescription to Utah

Patients relocating to Utah from another state can transfer an existing Farxiga prescription. Utah Board of Pharmacy rules allow interstate prescription transfers for non-controlled medications.

How the Transfer Works

Call your current out-of-state pharmacy and request a transfer to a Utah pharmacy. Provide the receiving pharmacy's name, address, and phone number. The pharmacies coordinate the transfer directly. If your insurance plan changes because of the move (common with employer-based plans), you may need a new prior authorization under the new plan. Your Utah provider can initiate this.

Establishing Care in Utah

Even with a valid transferred prescription, you should establish care with a Utah-licensed provider within 90 days. This ensures continuity of monitoring labs, refill management, and any future dose adjustments.

Rural Access Considerations

Utah's geography presents real access challenges. About 25% of the state's population lives outside the Wasatch Front metro corridor.

Mail-Order Pharmacy

Patients in St. George, Cedar City, Moab, Vernal, or other rural communities can use mail-order pharmacy services. Most commercial plans offer 90-day mail-order fills at a lower copay than 30-day retail fills. AstraZeneca's copay card works at mail-order pharmacies.

Telehealth Bridges the Gap

For patients 2 or more hours from a specialist, telehealth provides access to endocrinologists, cardiologists, and nephrologists who prescribe dapagliflozin regularly. Lab work can be drawn at the nearest regional hospital or independent lab.

The 2023 Endocrine Society clinical practice guideline recommends SGLT2 inhibitors as part of a glucose-lowering strategy that considers cardiovascular and renal comorbidities [9]. Telehealth ensures that guideline-concordant care reaches patients regardless of ZIP code.